uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Adrenocortical carcinoma: towards genomics guided clinical care
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Endokrin tumörbiologi.ORCID-id: 0000-0003-0677-4894
Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany;Univ Spital Zurich, Klin Endokrinol Diabetol & Klin Ernahrung, Zurich, Switzerland.ORCID-id: 0000-0001-7826-3984
2019 (engelsk)Inngår i: Nature Reviews Endocrinology, ISSN 1759-5029, E-ISSN 1759-5037, Vol. 15, nr 9, s. 548-560Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Adrenocortical carcinoma (ACC) is an aggressive and rare neoplasm that originates in the cortex of the adrenal gland. The disease is associated with heterogeneous but mostly poor outcomes and lacks effective pharmaceutical treatment options. Multi-omics studies have defined the landscape of molecular alterations in ACC. Specific molecular signatures can be detected in body fluids, potentially enabling improved diagnostic applications for patients with adrenal tumours. Importantly, pan-molecular data sets further reveal a spectrum within ACC, with three major subgroups that have different disease outcomes. These new subgroups have value as prognostic biomarkers. Research has revealed that the p53-RB and the WNT-beta-catenin pathways are common disease drivers in ACC. However, these pathways remain difficult to target by therapeutic interventions. Instead, a unique characteristic of ACC is steroidogenic differentiation, which has emerged as a potential treatment target, with several agents undergoing preclinical or clinical investigations. Finally, a large proportion of ACC tumours have genetic profiles that are associated with promising therapeutic responsiveness in other cancers. All these opportunities now await translation from the laboratory into the clinical setting, thereby offering a real potential of improved survival outcomes and increased quality of life for patients with this serious condition.

sted, utgiver, år, opplag, sider
2019. Vol. 15, nr 9, s. 548-560
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-393685DOI: 10.1038/s41574-019-0221-7ISI: 000480419200011PubMedID: 31147626OAI: oai:DiVA.org:uu-393685DiVA, id: diva2:1354606
Forskningsfinansiär
Swedish Cancer SocietyGerman Research Foundation (DFG), CRC/Transregio 205/1Wallenberg FoundationsTore Nilsons Stiftelse för medicinsk forskningTilgjengelig fra: 2019-09-25 Laget: 2019-09-25 Sist oppdatert: 2019-09-25bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Crona, Joakim

Søk i DiVA

Av forfatter/redaktør
Crona, JoakimBeuschlein, Felix
Av organisasjonen
I samme tidsskrift
Nature Reviews Endocrinology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 22 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf